While cannabis is known to have immunomodulatory properties, the clinical consequences of its use on outcomes in COVID-19 have not been extensively evaluated. We aimed to assess whether cannabis users hospitalized for COVID-19 had improved outcomes compared to non-users.
Dr. Sherry Yafai of the Releaf Institute gives the basics on the endocannabinoid system and cannabinoids. By the end of this lecture, participants will be able to describe the endocannabinoid system and relevant receptors, assess the current clinical evidence for cannabinoids as a therapeutic treatment option, and as well as discussing the need for further education for healthcare providers.
Members of the SCC International Committee share unique and challenging clinical cases from patients using medical cannabis treatment. Originally recorded on June 8th, 2020.
Kimberly Kirchmeyer of the Medical Board of California discusses the guidelines for recommending cannabis for medicinal purposes. This includes details on patient evaluation, shared decision making, qualifying conditions, treatment agreements, and conflicts of interest.
This review paper by Dr. Robert Silver gives an overview of the ECS in animals and highlights it as a topic of interest for emerging therapeutics.
Dr. Sherry Yafai is an ER doctor who also integrates cannabis-based medicine in her clinical practice at The Releaf Institute. In this interview with Joe Lemon, she explores the reasons why cannabis- informed healthcare providers are needed more and more.
Dr. Phillip Grob, a geriatric psychiatrist, discusses the potential applications of cannabis for dementia and mental health challenges in the senior population.
Dr. Sherry Yafai of the Releaf Institute discusses the applications of cannabis to reduce or replace the use of opiate drugs. She outlines the opioid epidemic and how cannabis may be used as a tool for harm reduction.
Dr. Cristina Sanchez, a biochemist with over 20 years of experience as a cannabinoid researcher, outlines the preclinical evidence of cannabinoids on different types of cancer.
Dr. Arno Hazekamp discusses the intricacies of the Sativa/Indica debate. He describes metabolic characterists of cannabis constituents and the characteristics of hybrids. Originally recorded at the SCC Quarterly Meeting in March of 2018.
Dr. Kirsten Muller-Vahl, is a physician specializing in neurology and psychiatry, is the world’s authority on cannabis and Tourette’s syndrome. She presents “Tourette Syndrome: Clinical presentation, underlying pathology and treatment options” at the February SCC Quarterly Meeting on January 4, 2018.
Dr. David (Dedi) Meiri presents on “Laboratory of Cancer Biology and Cannabinoid Research” at the SCC Quarterly Meeting on September 17, 2017